BiotechTube

EryDex Low dose DSP + EryDex High dose DSP + Pooled Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nervous System Disease

Conditions

Nervous System Disease, Genetic Syndrome

Trial Timeline

Mar 2, 2017 → May 13, 2021

NCT ID
NCT02770807

About EryDex Low dose DSP + EryDex High dose DSP + Pooled Placebo

EryDex Low dose DSP + EryDex High dose DSP + Pooled Placebo is a phase 3 stage product being developed by Quince Therapeutics for Nervous System Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02770807. Target conditions include Nervous System Disease, Genetic Syndrome.

What happened to similar drugs?

0 of 7 similar drugs in Nervous System Disease were approved

Approved (0) Terminated (0) Active (7)
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄temozolomideMerckPhase 3
🔄leflunomide + procarbazine hydrochloridePfizerPhase 3
🔄Gadobutrol (Gadavist, Gadovist, BAY86-4875) + MagnevistBayerPhase 3
🔄Gadobutrol (Gadavist, Gadovist, BAY86-4875)BayerPhase 3
🔄Botulinum toxin type A + Botulinum toxin type A + PlaceboIpsenPhase 3
🔄Botulinum toxin type AIpsenPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02770807Phase 3Completed

Competing Products

20 competing products in Nervous System Disease

See all competitors
ProductCompanyStageHype Score
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
29
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcoholEisaiPhase 1
29
perampanelEisaiPhase 2
35
Tirabrutinib + PlaceboOno PharmaceuticalPhase 2
42
TirabrutinibOno PharmaceuticalPhase 1
36
ONO-4059 + Rituximab + Methotrexate + Procarbazine + VincristineOno PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
47
Tirabrutinib + Tirabrutinib + TirabrutinibOno PharmaceuticalPhase 2
39
pemetrexedEli LillyPhase 1
29
HRS-9231 + GadobutrolJiangsu Hengrui MedicinePhase 2
42
AcalabrutinibAstraZenecaPhase 2
39
Durvalumab + AcalabrutinibAstraZenecaPhase 1
33
Avelumab + LenvatinibMerckPhase 1
33
temozolomideMerckPhase 3
44
Ibrutinib + Pembrolizumab + RituximabMerckPhase 1/2
39
TemozolomideMerckPhase 2
35
AEE788 + everolimusNovartisPhase 1/2
32
vatalanibNovartisPhase 2
35
EPO906 (epothilone B)NovartisPhase 1
29